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Reply: Late Gestation SSRI Exposure and Perinatal Mortality 
To the Editor: 
We appreciate the interest in our study investigating neonatal outcomes following late 
gestation exposure to selective serotonin reuptake inhibitors (SSRIs)1 and the call for 
additional analyses to examine clinical manifestations of the infants, in particular, fatal 
outcomes. Given the rarity of fatal outcomes, such as stillbirth (3.69 per 1,000)  and neonatal 
death (2.20 per 1,000)  as reported by Stephansson et al.2, our associated sample size was not 
sufficient to enable adequate statistical power to justify their investigation. We do, however, 
appreciate the significance of including data on infant mortality to more completely describe 
the effects of prenatal SSRI exposure on extreme clinical manifestations and the infant life-
prognosis. In accordance with this we have included data on stillbirths and neonatal death 
below. 
Our original analysis included the investigation of neonatal outcomes amongst live-
born singletons. After including data on infants previously excluded from the study (i.e. fetal 
deaths), there was only 1 (0.61%; 6.1 per 1,000 births) stillbirth in the group of women who 
received a dispensing for a SSRI, 14 (0.89%; 8.9 per 1,000 births) stillbirths in the group of 
women who had a documented psychiatric illness but did not receive a dispensing for a SSRI 
and 198 (0.45%; 4.5 per 1,000 births) stillbirths in the group of women who did not have a 
psychiatric illness and did not receive a dispensing for a SSRI. With recognised limitations of 
sample size set aside, these differences were not statistically significant. 
From the available data we can confirm that there were 2 (0.90%; 9.0 per 1,000 
births) neonatal deaths in the group of women who received a dispensing for a SSRI, 5 
(0.3%; 3.2 per 1,000 births) neonatal deaths in the group of women who had a documented 
psychiatric illness but did not received a dispensing for a SSRI and 96 (0.30%; 3.0 per 1,000 
births) neonatal deaths in the group of women who did not have a psychiatric illness and did 
not receive a dispensing for a SSRI. Again, with recognised limitations of sample size set 
aside, these differences were not statistically significant. Furthermore, no data were available 
to us in relation to the cause of death. 
Given the relatively small number of outcomes, we feel that these results should be 
interpreted with caution, making it difficult to draw accurate comparisons to previous studies, 
such as that published by Stephansson et al.2 An important note is that our overall rates of 
fatal outcomes in our cohort are higher than that identified by Stephansson et al.2 This could 
be a manifestation of our cohort being derived from a single specialist tertiary level teaching 
hospital that is likely to attract high-risk pregnancies1, as opposed to the population based 
approach undertaken by Stephansson et al.2 We also acknowledge the limitation of not having 
data available to assess severity of underlying maternal illness. Further studies with adequate 
sample size are required to clarify these findings and we look forward to this evolving 
literature. 
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